CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.
Our lead candidate, CG0070, is a selective oncolytic immunotherapy in multiple clinical programs, including ongoing trials with CG0070 as a monotherapy in a global Phase 3 study (BOND3) for the treatment of BCG-unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC), and also in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 study (CORE1) in the same indication. Additional indications in muscle-invasive bladder cancer (MIBC) and other solid tumors are being pursued with CG0070 in combination with immune checkpoint modulators.
At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.